FDA Adverse Event Injury Summary report: N

ALIGN TO URETHRAL SUPPORT SYSTEM

MDR report key: 3121881 · Received May 15, 2013

Report

Report Number
1018233-2013-01969
Event Type
Injury
Date Received
May 15, 2013
Report Date
October 26, 2017
Manufacturer
C.R. BARD, INC. (COVINGTON) -1018233
Product Code
OTN
UDI-DI
00801741016219
PMA / PMN Number
K070073
Removal / Correction Number
NA
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
KS, US
Reporter Occupation
ATTORNEY
Health Professional
N

Narratives

Additional Manufacturer Narrative · 1

THE SAMPLE WAS NOT RETURNED. THE FINISHED PRODUCT MET ALL SPECS PRIOR TO BEING RELEASED FOR GENERAL DISTRIBUTION. THE INSTRUCTIONS FOR USE WHICH ACCOMPANIES ALL DEVICES CURRENTLY ADDRESSES POTENTIAL RISKS ASSOCIATED WITH SURGICALLY IMPLANTED MATERIALS. THE INSTRUCTIONS FOR USE STATES IN THE ADVERSE EVENTS: "COMPLICATIONS ASSOCIATED WITH THE PROPER IMPLANTATION OF THE ALIGN URETHRAL SUPPORT SYSTEM MAY INCLUDE, BUT ARE NOT LIMITED TO: POSTOPERATIVE HEMATOMA, WHICH MAY OCCUR FOLLOWING THE IMPLANT PROCEDURE. TEMPORARY URINARY RETENTION, BLADDER OUTLET OBSTRUCTION, AND VOIDING DIFFICULTIES ASSOCIATED WITH OVER-CORRECTION/TOO MUCH TENSION PLACED ON THE MESH SLING IMPLANT. PERFORATIONS OR LACERATIONS OF VESSELS, NERVES, BLADDER OR ANY VISCERA, WHICH MAY OCCUR DURING INTRODUCER NEEDLE PASSAGE. TRANSITORY IRRITATION AT THE OPERATIVE WOUND SITE, WHICH MAY ELICIT A FOREIGN BODY RESPONSE THAT LEADS TO INFLAMMATION, INFECTION, OR EROSION OF THE IMPLANT". (B)(4).

Description of Event or Problem · 1

THE PT'S ATTORNEY ALLEGED A DEFICIENCY AGAINST THE DEVICE. PER ADD'L INFO RECEIVED, THE PT HAS EXPERIENCED INCONTINENCE, INFECTIONS AND TROUBLE EMPTYING BLADDER. (B)(4).

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
215037 ALIGN TO URETHRAL SUPPORT SYSTEM No Match OTN C.R. BARD, INC. (COVINGTON) -1018233 NA HUTJ0107 00801741016219
215038 ALIGN TO URETHRAL SUPPORT SYSTEM No Match OTN C.R. BARD, INC. (COVINGTON) -1018233 NA HUTJ0107 00801741016219

Patients

Seq Age Sex Outcome Treatment
1 36 YR Female Required Intervention